OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases


6 February 2018
Frankfurt MidCap Event

12-14 March 2018
BIO-Europe Spring, Amsterdam

4-5 April 2018
Conference Portzamparc MidCap

OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation. These new generation products are optimized to better target key receptors of the immune response’s activation or regulation, thus allowing for longer therapeutic effects.

The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

Its first-in-class clinical portfolio offers a diversified risk profile.